No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Elosulfase Alfa is a recombinant human lysosomal enzyme used to treat Mucopolysaccharidosis IVA (MPS IVA), a rare, inherited metabolic disorder. It is a member of the Endocrine and Metabolic Disorders Drugs class, which includes drugs used to treat a variety of conditions, such as diabetes, obesity, and thyroid disorders. Elosulfase Alfa works by replacing the missing enzyme in the body, allowing it to break down and remove glycosaminoglycans (GAGs) from the cells. This helps to reduce the symptoms of MPS IVA, such as skeletal and joint abnormalities, hearing loss, and respiratory problems.
Elosulfase Alfa is available in the United States, Europe, and other countries. It is marketed by Shire Pharmaceuticals, a subsidiary of Takeda Pharmaceuticals, and is also available as a generic drug. Other companies in the market include Sanofi, Pfizer, and Novartis. Show Less Read more
